Lexeo Finalizes Pivotal Trial Design for Friedreich Ataxia Gene Therapy
Event summary
- Lexeo Therapeutics finalized the SUNRISE-FA 2 pivotal trial protocol for LX2006 gene therapy in Friedreich ataxia (FA), targeting a 2028 BLA submission under accelerated approval.
- The open-label study will enroll 13 participants treated with LX2006 and 13 untreated controls, with a primary endpoint of left ventricular mass index (LVMI) assessed via cardiac MRI at 6 months.
- First patient enrollment in SUNRISE-FA 2 is expected by the end of June 2026, with topline data readout anticipated in the second half of 2027.
- The FDA confirmed no additional nonclinical bridging studies are required, allowing Lexeo to use its optimized manufacturing process for the pivotal study.
The big picture
Lexeo's finalization of the SUNRISE-FA 2 trial design marks a critical step in advancing LX2006 as a potential first-in-class gene therapy for FA cardiomyopathy. The open-label design and focus on LVMI as the primary endpoint reflect the FDA's evolving approach to gene therapy trials, prioritizing clinical outcomes over mechanistic proof. The study's initiation in Q2 2026 positions Lexeo to capitalize on the growing demand for genetic medicines targeting rare cardiovascular diseases, though success will hinge on flawless trial execution and manufacturing readiness.
What we're watching
- Regulatory Pathway
- Whether the FDA's acceptance of the accelerated approval pathway for LX2006 will streamline the regulatory process and reduce execution risk.
- Trial Execution
- The pace at which Lexeo can enroll patients and generate topline data from the SUNRISE-FA 2 study, given the tight timeline for a 2028 BLA submission.
- Manufacturing Scalability
- How Lexeo's optimized manufacturing process will scale to meet commercial demand if LX2006 receives regulatory approval.
Related topics